Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 22:13:928550.
doi: 10.3389/fneur.2022.928550. eCollection 2022.

Phenytoin as seizure prophylaxis in hematopoietic stem cell transplantation with busulfan conditioning

R S Germeraad  1 , A M P Demandt  2 , R P W Rouhl  1   3   4
Affiliations

Phenytoin as seizure prophylaxis in hematopoietic stem cell transplantation with busulfan conditioning

R S Germeraad et al. Front Neurol. .

Abstract

Background: Phenytoin is widely used as primary seizure prophylaxis in hematopoietic stem cell transplantation in patients undergoing myeloablative conditioning with busulfan. Because of the negative side effects of phenytoin, we abandoned phenytoin use in these patients. To assess the effect of this change, we performed a retrospective cohort study on all patients receiving busulfan.

Methods: We included 139 patients who underwent conditioning with busulfan for hematopoietic stem cell therapy. We registered the use of phenytoin, as well as the occurrence of seizures, until 7 days after busulfan administration. We compared seizure incidence between patients who received phenytoin and those who did not.

Results: Of the 43 patients who received phenytoin prophylaxis, four patients (9.3%) had a seizure during the conditioning regimen, of which two patients had cerebral non-Hodgkin lymphoma. Furthermore, all these 4 patients had very high levels of phenytoin (intoxication). Of the 96 patients that did not receive phenytoin prophylaxis, three patients (3.1%) had a seizure, and one of these patients had an undefined cerebral lesion. Phenytoin did not relate to seizure prevention in a logistic regression analysis.

Conclusion: We conclude that phenytoin prophylaxis in patients treated with busulfan is obsolete and possibly harmful, as phenytoin intoxication can occur. We recommend discontinuing the use of phenytoin as primary seizure prophylaxis in these patients.

Keywords: acute symptomatic seizure; busulfan; phenytoin (PHT); seizure; seizure prophylaxis.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. Santos GW, Tutschka PJ. Marrow transplantation in the busulfan-treated rat: preclinical model of aplastic anemia. J Natl Cancer Inst. (1974) 53:1781–5. - PubMed
    1. Hassan M, Oberg G, Ehrsson H, Ehrnebo M, Wallin I, Smedmyr B, et al. . Pharmacokinetic and metabolic studies of high-dose busulphan in adults. Eur J Clin Pharmacol. (1989) 36:525–30. 10.1007/BF00558081 - DOI - PubMed
    1. Bartelink IH, Lalmohamed A, van Reij EM, Dvorak CC, Savic RM, Zwaveling J, et al. . Association of busulfan exposure with survival and toxicity after hemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis. Lancet Haematol. (2016) 3:e526–e36. 10.1016/S2352-3026(16)30114-4 - DOI - PMC - PubMed
    1. Eberly AL, Anderson GD, Bubalo JS, McCune JS. Optimal prevention of seizures induced by high-dose busulfan. Pharmacotherapy. (2008) 28:1502–10. 10.1592/phco.28.12.1502 - DOI - PubMed
    1. Kobayashi R, Watanabe N, Iguchi A, Cho Y, Yoshida M, Arioka H, et al. . Electroencephalogram abnormality and high-dose busulfan in conditioning regimens for stem cell transplantation. Bone Marrow Transplant. (1998) 21:217–20. 10.1038/sj.bmt.1701076 - DOI - PubMed

LinkOut - more resources